AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 296 min read$BLKB

BLACKBAUD INC (BLKB): Results of Operations and Financial Condition

BLACKBAUD INC (BLKB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 blkbq22026exhibit991.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Blackbaud Announces 2026 Second Quarter Results Company Expects to Finish Fiscal Year 2026 in the Upper Half of Financial Guidance Ranges Charleston, S.C. (July 29, 2026) — Blackbaud (NASDAQ: BLKB), th

Original reporting
SEC EDGAR 8-K
Published Jul 29, 2026, 11:11 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$BLKB
Bullish
high confidence
Mentioned
$BLKB
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BLKBBullishMed
01

Why it matters

Traders can update models using the reported Q2 figures and the reaffirmed FY26 ranges, then reassess valuation sensitivity to free cash flow and buyback pace.

02

Market read

Q2 performance and reaffirmed FY26 guidance with upper-half framing, plus explicit free-cash-flow and repurchase expectations, are the core trading inputs.

03

What to watch

The guidance is reaffirmed rather than raised, so upside may be capped unless investors view the upper-half expectation as effectively incremental.

Relevance 7/10Novelty 8/10Timing: after-hours earnings release and FY26 guidance reaffirmation (July 29, 2026)

Background

This SEC 8-K (Item 2.02) attaches Blackbaud’s Q2 2026 results press release and reiterates full-year guidance, including updated assumptions and repurchase plans.

Company-level read

Ticker impact

$BLKBBullishHigh confidence
Context

Blackbaud reported Q2 ended June 30, 2026 results and reaffirmed FY26 guidance, expecting to finish in the upper half of ranges.

Expected impact

Likely supportive for near-term sentiment, especially if investors focus on upper-half guidance framing and free-cash-flow strength.

Evidence & confidence

The filing includes specific Q2 metrics (revenue, operating income, EPS, free cash flow) and a concrete FY26 guidance range plus updated assumptions, which are actionable for positioning into the next earnings cycle.

Market effects

Sector

Reinforces demand and monetization momentum in social-impact software, with emphasis on AI-first, cloud-native product strategy.

Regional

No specific regional read-through beyond general US software/enterprise SaaS sentiment.

Global

Limited direct global impact stated; story is company-specific with no international regulatory or macro shocks mentioned.

Counterpoint

What could challenge this read

Non-GAAP operating margin declined 110 bps and adjusted EBITDA margin fell 70 bps, suggesting cost or investment pressure despite revenue growth.

Key entities

  • company
    Blackbaud

    Provider of AI-powered solutions for social impact; reported Q2 2026 results and reaffirmed FY26 guidance.

  • executive
    Mike Gianoni

    CEO/president who stated the company expects to finish in the upper half of FY26 guidance ranges.

  • executive
    Chad Anderson

    CFO who discussed execution against the operating plan and ongoing share repurchases.

Read at source← All news

Related articles

JUL 29
$BLKBMedAI 8/10

Why Blackbaud Stock Is Skyrocketing Today

Blackbaud (BLKB) shares rose about 20.5% on Wednesday after the company’s Q2 results. Blackbaud reported non-GAAP earnings of $1.33 on revenue of $290.6 million, with adjusted EPS above estimates but sales $1.76 million below. It reiterated full-year adjusted EPS guidance of $5.15 to $5.25 and said results are expected in the upper half of guidance.

fool.com4 min
JUL 29
$BLKBMedAI 8/10

Blackbaud Announces 2026 Second Quarter Results

Blackbaud (NASDAQ: BLKB) reported Q2 2026 results for the quarter ended June 30, 2026. GAAP total revenue was $290.6 million (+3.0%) and GAAP diluted EPS was $0.79. Non-GAAP diluted EPS was $1.33. The company expects FY2026 to finish in the upper half of guidance, including GAAP revenue $1.173B-$1.179B and non-GAAP FCF $280M-$290M, and reiterated repurchases of 6%-10% of shares.

prnewswire.com4 min
AUG 8
$NNNMed

NNN REIT Q2 Earnings Call Highlights

NNN REIT (NYSE:NNN) reported Q2 earnings call highlights. It cut its full-year bad-debt outlook to about 40 bps from 60 bps, kept second-half credit-loss assumptions, and raised the annual disposition guidance midpoint by $10 million to $140 million. In Q2 it invested $290M in 89 properties, occupancy rose to 99.1%, and it declared a $0.62/share dividend.

yahoo.com6 min
AUG 8
$NTRMed

Nutrien Q2 Earnings Call Highlights

Nutrien’s CEO Ken Seitz said the company used automation to mine 53% of ore tons in the first half, exceeding its 2024 target range. Nutrien maintained 2026 potash shipment guidance of 74-77 million tons and 2026 nitrogen sales-volume guidance of 9.2-9.7 million tons. Q2 nitrogen adjusted EBITDA was $635 million. The company cut 2026 capex guidance to $1.95B-$2.05B and raised share repurchases to about $75M/month.

yahoo.com6 min
AUG 8
$NVGSMed

Navigator Q2 Earnings Call Highlights

Navigator Holdings (NYSE:NVGS) reported Q2 updates. Its 2026 all-in cash breakeven rose to $21,990 per vessel per day from $21,230, citing the pending sale of eight Unigas Pool vessels. Morgan’s Point ethylene terminal set a record 374,278 tonnes; Navigator’s equity income was $7.1m. It sold Navigator Pegasus for $30.5m and expects Unigas sales net proceeds about $129m and book gains $65m-$70m. Dividend $0.07/share; Q3 TCE and volumes expected to moderate.

yahoo.com6 min
AUG 8
$NUVBMed

Nuvation Bio Q2 Earnings Call Highlights

Nuvation Bio (NUVB) reported Q2 call highlights for IBTROZI in ROS1-positive lung cancer, citing TRUST-I results in TKI-naive patients with a 90% objective response rate and 50-month median response duration and progression-free survival. The company said first-line ROS1 TKI use rose nearly 20% through May 2026. It also updated safusidenib Phase II J201 (52% ORR, 79% 36-month PFS) and outlined Phase III/G307 and G209 studies. Cash was $661M after a June convertible notes offering.

yahoo.com6 min